A study in Psychology of Addictive Behaviors finds teens who have more demand for cannabis are likely to use it for enjoyment and coping. Understanding motives is important for addiction prevention.
Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis.
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.
MD Anderson and Rigel Pharmaceuticals announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia and other hematologic cancers.
20221027104337.jpg&width=400&height=400)
The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
CRI's 2023 Patient Immunotherapy Summit is now available on-demand for the benefit of cancer patients, families, caregivers, and scientists.
Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.
In a new study published in the Journal for ImmunoTherapy of Cancer, a team of researchers from the Donald A. Adam Melanoma and Skin Cancer Center of Excellence at Moffitt Cancer Center reveals differences in the mechanisms of action of two FDA-approved immune checkpoint inhibitor combination therapies for advanced melanoma.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
NCCN—an alliance of leading cancer centers—hosted a Patient Advocacy Summit to explore the role of navigation throughout the cancer process. A diverse group of subject matter experts addressed the impact patient navigation has on care and how to utilize navigators to reduce economic burdens and disparities in care.
Three physician-scientists who have relocated to Buffalo, New York, to join Roswell Park Comprehensive Cancer Center will apply highly specialized transplantation and cell therapy (TCT) expertise to both patient care and the development of New York State’s first cell therapy manufacturing and research hub. Brian Betts, MD, has joined Roswell Park as Vice Chair of Strategic Initiatives within the Transplant & Cellular Therapy Section, Department of Medicine; Kanwaldeep Mallhi, MD, was named Associate Professor of Oncology and Clinical Director of Pediatric Transplantation and Cellular Therapy in the Department of Pediatrics; and Shernan Holtan, MD, will join the Roswell Park faculty in February as Chief of Blood and Marrow Transplant in the Department of Medicine.
Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at The University of Texas MD Anderson Cancer Center, has been honored with the E. Donnall Thomas Lecture and Prize from the American Society of Hematology (ASH, for her groundbreaking research to develop and advance innovative cell therapies for cancer using natural killer (NK) cells.
Incorporating navy beans into the diet of colorectal cancer survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.
Researchers at the UC Davis Comprehensive Cancer Center have discovered that using gene therapy to inhibit a specific protein, galectin 1, can shrink liver cancer tumors in an animal model.
SEATTLE — Nov. 30, 2023 — The 65th Annual Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 9-13.Below are highlights of Fred Hutchinson Cancer Center research to be presented and experts available to comment on news.
George Demetri, MD, director of the Sarcoma Center at Dana-Farber Cancer Institute, is being awarded the prestigious J.E. Wallace Sterling Lifetime Achievement Award in Medicine from the Stanford Medicine Alumni Association (SMAA).
The Latin American and Caribbean Society of Medical Oncology (SLACOM) and National Comprehensive Cancer Network (NCCN) host the Latin American Regional Breast Cancer Summit: Advocating and Implementing Guideline-Concordant Cancer Care for Patients. Esteemed experts from Argentina, Brazil, Mexico, Columbia, Peru, and the United States present challenges, barriers, and potential solutions for improving access to guideline-concordant breast cancer care in the Latin American region.
Moffitt Cancer Center has received a $3.6 million grant from the National Institute of Dental and Craniofacial Research (U01DE033329) to further groundbreaking research that has unveiled a promising noninvasive diagnostic biomarker panel for the early detection of oropharyngeal cancer.
Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9. The international symposium provides leading-edge breast cancer information on prevention, etiology, diagnosis, and therapy as well as experimental biology. This year’s symposium, at the Henry B.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right